ANGIODYNAMICS INC (ANGO) Stock Fundamental Analysis

NASDAQ:ANGO • US03475V1017

11.13 USD
-0.13 (-1.15%)
At close: Feb 18, 2026
11.13 USD
0 (0%)
After Hours: 2/18/2026, 8:14:16 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ANGO. ANGO was compared to 185 industry peers in the Health Care Equipment & Supplies industry. ANGO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ANGO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ANGO has reported negative net income.
  • In the past year ANGO has reported a negative cash flow from operations.
  • In the past 5 years ANGO always reported negative net income.
  • In multiple years ANGO reported negative operating cash flow during the last 5 years.
ANGO Yearly Net Income VS EBIT VS OCF VS FCFANGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • ANGO's Return On Assets of -10.28% is fine compared to the rest of the industry. ANGO outperforms 61.08% of its industry peers.
  • ANGO has a Return On Equity of -15.71%. This is in the better half of the industry: ANGO outperforms 62.70% of its industry peers.
Industry RankSector Rank
ROA -10.28%
ROE -15.71%
ROIC N/A
ROA(3y)-26.67%
ROA(5y)-18.08%
ROE(3y)-40.7%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
ANGO Yearly ROA, ROE, ROICANGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • ANGO has a Gross Margin of 54.58%. This is comparable to the rest of the industry: ANGO outperforms 54.05% of its industry peers.
  • In the last couple of years the Gross Margin of ANGO has remained more or less at the same level.
  • ANGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y-1.07%
ANGO Yearly Profit, Operating, Gross MarginsANGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ANGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ANGO has been increased compared to 1 year ago.
  • Compared to 5 years ago, ANGO has more shares outstanding
  • The debt/assets ratio for ANGO is higher compared to a year ago.
ANGO Yearly Shares OutstandingANGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ANGO Yearly Total Debt VS Total AssetsANGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • ANGO has an Altman-Z score of 1.91. This is not the best score and indicates that ANGO is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ANGO (1.91) is better than 61.08% of its industry peers.
  • A Debt/Equity ratio of 0.03 indicates that ANGO is not too dependend on debt financing.
  • With a decent Debt to Equity ratio value of 0.03, ANGO is doing good in the industry, outperforming 69.19% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.91
ROIC/WACCN/A
WACC9.98%
ANGO Yearly LT Debt VS Equity VS FCFANGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • ANGO has a Current Ratio of 2.24. This indicates that ANGO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ANGO (2.24) is comparable to the rest of the industry.
  • A Quick Ratio of 1.33 indicates that ANGO should not have too much problems paying its short term obligations.
  • ANGO has a worse Quick ratio (1.33) than 62.70% of its industry peers.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 1.33
ANGO Yearly Current Assets VS Current LiabilitesANGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 72.97% over the past year.
  • Looking at the last year, ANGO shows a small growth in Revenue. The Revenue has grown by 7.26% in the last year.
  • The Revenue has been growing slightly by 2.06% on average over the past years.
EPS 1Y (TTM)72.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)7.26%
Revenue growth 3Y-2.56%
Revenue growth 5Y2.06%
Sales Q2Q%9.04%

3.2 Future

  • Based on estimates for the next years, ANGO will show a very strong growth in Earnings Per Share. The EPS will grow by 33.95% on average per year.
  • Based on estimates for the next years, ANGO will show a small growth in Revenue. The Revenue will grow by 5.85% on average per year.
EPS Next Y-97.2%
EPS Next 2Y11.89%
EPS Next 3Y50.78%
EPS Next 5Y33.95%
Revenue Next Year9.15%
Revenue Next 2Y7.02%
Revenue Next 3Y6.49%
Revenue Next 5Y5.85%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ANGO Yearly Revenue VS EstimatesANGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ANGO Yearly EPS VS EstimatesANGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • ANGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGO Price Earnings VS Forward Price EarningsANGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

  • 63.24% of the companies in the same industry are more expensive than ANGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 133.86
ANGO Per share dataANGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ANGO's earnings are expected to grow with 50.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.89%
EPS Next 3Y50.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ANGO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANGIODYNAMICS INC

NASDAQ:ANGO (2/18/2026, 8:14:16 PM)

After market: 11.13 0 (0%)

11.13

-0.13 (-1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-06
Earnings (Next)03-31
Inst Owners97.53%
Inst Owner Change0.21%
Ins Owners6.13%
Ins Owner Change0.67%
Market Cap458.78M
Revenue(TTM)307.31M
Net Income(TTM)-27.71M
Analysts84
Price Target19.72 (77.18%)
Short Float %5.35%
Short Ratio3.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)58.28%
Min EPS beat(2)16.56%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)78.67%
Min EPS beat(4)16.56%
Max EPS beat(4)122.62%
EPS beat(8)7
Avg EPS beat(8)56.78%
EPS beat(12)9
Avg EPS beat(12)16.11%
EPS beat(16)12
Avg EPS beat(16)37.25%
Revenue beat(2)2
Avg Revenue beat(2)2.06%
Min Revenue beat(2)2.06%
Max Revenue beat(2)2.06%
Revenue beat(4)4
Avg Revenue beat(4)2.59%
Min Revenue beat(4)0.41%
Max Revenue beat(4)5.83%
Revenue beat(8)5
Avg Revenue beat(8)0.5%
Revenue beat(12)5
Avg Revenue beat(12)-0.72%
Revenue beat(16)6
Avg Revenue beat(16)-1%
PT rev (1m)0%
PT rev (3m)4.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)12.12%
EPS NY rev (3m)12.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.49
P/FCF N/A
P/OCF N/A
P/B 2.6
P/tB 4.19
EV/EBITDA 133.86
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS7.46
BVpS4.28
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.28%
ROE -15.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.58%
FCFM N/A
ROA(3y)-26.67%
ROA(5y)-18.08%
ROE(3y)-40.7%
ROE(5y)-27.1%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y-1.07%
F-Score5
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 1.77
Cap/Depr 15.59%
Cap/Sales 1.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 1.33
Altman-Z 1.91
F-Score5
WACC9.98%
ROIC/WACCN/A
Cap/Depr(3y)17.4%
Cap/Depr(5y)17.38%
Cap/Sales(3y)1.57%
Cap/Sales(5y)1.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y-97.2%
EPS Next 2Y11.89%
EPS Next 3Y50.78%
EPS Next 5Y33.95%
Revenue 1Y (TTM)7.26%
Revenue growth 3Y-2.56%
Revenue growth 5Y2.06%
Sales Q2Q%9.04%
Revenue Next Year9.15%
Revenue Next 2Y7.02%
Revenue Next 3Y6.49%
Revenue Next 5Y5.85%
EBIT growth 1Y34.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year151.66%
EBIT Next 3Y59.83%
EBIT Next 5Y38.19%
FCF growth 1Y-46.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.57%
OCF growth 3YN/A
OCF growth 5YN/A

ANGIODYNAMICS INC / ANGO FAQ

What is the fundamental rating for ANGO stock?

ChartMill assigns a fundamental rating of 2 / 10 to ANGO.


Can you provide the valuation status for ANGIODYNAMICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ANGIODYNAMICS INC (ANGO). This can be considered as Overvalued.


Can you provide the profitability details for ANGIODYNAMICS INC?

ANGIODYNAMICS INC (ANGO) has a profitability rating of 2 / 10.


Can you provide the financial health for ANGO stock?

The financial health rating of ANGIODYNAMICS INC (ANGO) is 3 / 10.


What is the earnings growth outlook for ANGIODYNAMICS INC?

The Earnings per Share (EPS) of ANGIODYNAMICS INC (ANGO) is expected to decline by -97.2% in the next year.